Q&A: Analyst-turned biotech exec-turned analyst reads the biotech Q1 tea leaves

The coronavirus pandemic is in full swing. Biopharma R&D and regulatory timelines have been disrupted, supply chains interrupted and what the future holds is anybody’s guess. Now with the first quarter having come to a close, what can we expect in earnings reports?

Endpoints News caught up with Yaron Werber, managing director and senior research analyst on Cowen’s biotechnology team for some crystal-ball gazing.